(VIANEWS) – Ritchie Bros. Auctioneers Incorporated (RBA), Saratoga Investment Corp New (SAR), Exelixis (EXEL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Ritchie Bros. Auctioneers Incorporated (RBA)
165.2% sales growth and 3.45% return on equity
Ritchie Bros. Auctioneers Incorporated, an asset management and disposition company, sells industrial equipment and other durable assets through its unreserved auctions, online marketplaces, listing services, and private brokerage services. It sells a range of used and unused commercial assets, including earthmoving equipment, truck tractors and trailers, government surplus, oil and gas equipment, and other industrial assets, as well as construction and heavy machinery. The company also offers live auction events with online bidding. It sells used equipment to its customers through live unreserved auctions at 40 auction sites worldwide. The company serves construction, transportation, agriculture, energy, oil and gas, mining, and forestry sectors. It operates in the United States, Canada, Australia, the United Arab Emirates, the Netherlands, Europe, the Middle East, Asia, and internationally. Ritchie Bros. Auctioneers Incorporated was founded in 1958 and is headquartered in Burnaby, Canada.
Earnings Per Share
As for profitability, Ritchie Bros. Auctioneers Incorporated has a trailing twelve months EPS of $0.98.
PE Ratio
Ritchie Bros. Auctioneers Incorporated has a trailing twelve months price to earnings ratio of 56.07. Meaning, the purchaser of the share is investing $56.07 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.45%.
Sales Growth
Ritchie Bros. Auctioneers Incorporated’s sales growth is 116.6% for the present quarter and 165.2% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 30.1%, now sitting on 1.85B for the twelve trailing months.
2. Saratoga Investment Corp New (SAR)
61.8% sales growth and 7.02% return on equity
Saratoga Investment Corp. is a business development company specializing in leveraged and management buyouts, acquisition financings, growth financings, recapitalization, debt refinancing, and transitional financing transactions at the lower end of middle market companies. It structures its investments as debt and equity by investing through first and second lien loans, mezzanine debt, co-investments, select high yield bonds, senior secured bonds, unsecured bonds, and preferred and common equity. The firm prefers to invest in aerospace, automotive aftermarket and services, business products and services, consumer products and services, education, environmental services, industrial services, financial services, food and beverage, healthcare products and services, logistics, distribution, manufacturing, restaurants services, food services, software services, technology services, specialty chemical, media and telecommunications. It seeks to invest in the United States. The firm primarily invests $5 million to $50 million in companies having EBITDA of $2 million or greater and revenues of $8 million to $250 million. The firm prefer to take a majority stake. It invests through direct lending as well as participation in loan syndicates. The firm was formerly known as GSC Investment Corp. Saratoga Investment Corp. is based in New York, New York with an additional office in Florham Park, New Jersey.
Earnings Per Share
As for profitability, Saratoga Investment Corp New has a trailing twelve months EPS of $2.06.
PE Ratio
Saratoga Investment Corp New has a trailing twelve months price to earnings ratio of 13.59. Meaning, the purchaser of the share is investing $13.59 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.02%.
Moving Average
Saratoga Investment Corp New’s worth is way above its 50-day moving average of $25.26 and way above its 200-day moving average of $25.03.
3. Exelixis (EXEL)
14% sales growth and 6.34% return on equity
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Earnings Per Share
As for profitability, Exelixis has a trailing twelve months EPS of $0.47.
PE Ratio
Exelixis has a trailing twelve months price to earnings ratio of 40.62. Meaning, the purchaser of the share is investing $40.62 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.34%.
4. Maximus (MMS)
9.9% sales growth and 10.91% return on equity
MAXIMUS, Inc. provides business process services (BPS) to government health and human services programs worldwide. It operates through three segments: U.S. Health and Human Services, U.S. Federal Services, and Outside the U.S. The U.S. Health and Human Services segment offers various BPS, appeals, and assessments for state, provincial, and national government programs, including Medicaid, Children's Health Insurance Program, Affordable Care Act, Health Insurance British Columbia, Health Assessment Advisory Service contract, and Preadmission Screening and Resident Reviews. This segment offers program eligibility support and enrollment; application assistance and independent health plan enrollment counseling; and beneficiary outreach, education, eligibility, enrollment, and renewal. It also provides independent disability, long-term sick, and other health assessment; specialized consulting; and centralized multilingual customer contact centers and multichannel self-service options for enrollment. The U.S. Federal Services segment offers centralized citizen engagement centers and support services; document and record management; case management, citizen support, and consumer education; independent medical reviews and worker's compensation benefit appeals; and Medicare and Medicaid appeals, and program eligibility appeals. It also provides modernization of systems and information technology infrastructure; infrastructure operations and support services; software development, operations, and management services; and data analytics services. The Outside the U.S. segment offers BPS solutions for governments and commercial clients outside the United States, including health and disability assessments, program administration for welfare-to-work services, and other related services. The company was founded in 1975 and is headquartered in Reston, Virginia.
Earnings Per Share
As for profitability, Maximus has a trailing twelve months EPS of $2.8.
PE Ratio
Maximus has a trailing twelve months price to earnings ratio of 29.94. Meaning, the purchaser of the share is investing $29.94 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.91%.
Sales Growth
Maximus’s sales growth is 7% for the current quarter and 9.9% for the next.
5. Universal Health Services (UHS)
7.3% sales growth and 11.12% return on equity
Universal Health Services, Inc., through its subsidiaries, owns and operates acute care hospitals, and outpatient and behavioral health care facilities. The company operates through Acute Care Hospital Services and Behavioral Health Care Services segments. Its hospitals offer general and specialty surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic and coronary care, pediatric services, pharmacy services, and/or behavioral health services. The company also provides commercial health insurance services; and various management services, which include central purchasing, information, finance and control systems, facilities planning, physician recruitment, administrative personnel management, marketing, and public relations services. Universal Health Services, Inc. founded in 1978 and is headquartered in King of Prussia, Pennsylvania.
Earnings Per Share
As for profitability, Universal Health Services has a trailing twelve months EPS of $9.4.
PE Ratio
Universal Health Services has a trailing twelve months price to earnings ratio of 14.51. Meaning, the purchaser of the share is investing $14.51 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.12%.
Sales Growth
Universal Health Services’s sales growth is 5.4% for the ongoing quarter and 7.3% for the next.
Moving Average
Universal Health Services’s value is higher than its 50-day moving average of $136.02 and higher than its 200-day moving average of $125.87.
6. Pacific Gas & Electric Co. (PCG)
6.9% sales growth and 8.38% return on equity
PG&E Corporation, through its subsidiary, Pacific Gas and Electric Company, engages in the sale and delivery of electricity and natural gas to customers in northern and central California, the United States. It generates electricity using nuclear, hydroelectric, fossil fuel-fired, fuel cell, and photovoltaic sources. The company owns and operates interconnected transmission lines; electric transmission substations, distribution lines, transmission switching substations, and distribution substations; and natural gas transmission, storage, and distribution system consisting of distribution pipelines, backbone and local transmission pipelines, and various storage facilities. It serves residential, commercial, industrial, and agricultural customers, as well as natural gas-fired electric generation facilities. The company was incorporated in 1905 and is based in Oakland, California.
Earnings Per Share
As for profitability, Pacific Gas & Electric Co. has a trailing twelve months EPS of $0.86.
PE Ratio
Pacific Gas & Electric Co. has a trailing twelve months price to earnings ratio of 19.7. Meaning, the purchaser of the share is investing $19.7 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.38%.
Yearly Top and Bottom Value
Pacific Gas & Electric Co.’s stock is valued at $16.94 at 01:22 EST, below its 52-week high of $17.68 and way higher than its 52-week low of $9.64.
Revenue Growth
Year-on-year quarterly revenue growth grew by 7.1%, now sitting on 22.09B for the twelve trailing months.
Sales Growth
Pacific Gas & Electric Co.’s sales growth is 9.7% for the present quarter and 6.9% for the next.
Volume
Today’s last reported volume for Pacific Gas & Electric Co. is 12063100 which is 24.57% below its average volume of 15992800.
7. FVCBankcorp (FVCB)
6.3% sales growth and 9.38% return on equity
FVCBankcorp, Inc. operates as the holding company for FVCbank that provides various banking products and services in Virginia. It offers deposit products, including interest and noninterest-bearing transaction accounts, checking and savings accounts, money market accounts, and certificates of deposit. The company also provides commercial real estate loans; commercial construction loans; commercial loans for various business purposes, such as for working capital, equipment purchases, lines of credit, and government contract financing; SBA loans; asset based loans and accounts receivable financing; home equity loans; and consumer loans. In addition, it offers business and consumer credit cards; merchant services; business insurance products; and online banking, remote deposit, and mobile banking services. The company serves the banking needs of commercial businesses, nonprofit organizations, professional service entities, and their respective owners and employees located in the greater Washington, D.C. and Baltimore metropolitan areas. FVCBankcorp, Inc. operates through a main office in Fairfax, Virginia. It also operates a network of 11 additional branch offices in Arlington, Virginia; Ashburn, Loudoun County, Virginia; the independent city of Manassas, Virginia; Reston, Fairfax County, Virginia; Springfield, Fairfax County, Virginia; and Montgomery County and Baltimore, Maryland, a loan production office in Lutherville, Maryland. FVCBankcorp, Inc. was founded in 2007 and is headquartered in Fairfax, Virginia.
Earnings Per Share
As for profitability, FVCBankcorp has a trailing twelve months EPS of $1.04.
PE Ratio
FVCBankcorp has a trailing twelve months price to earnings ratio of 10.35. Meaning, the purchaser of the share is investing $10.35 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.38%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 44%, now sitting on 58.27M for the twelve trailing months.
Moving Average
FVCBankcorp’s worth is higher than its 50-day moving average of $9.83 and way under its 200-day moving average of $13.44.
Yearly Top and Bottom Value
FVCBankcorp’s stock is valued at $10.76 at 01:22 EST, way under its 52-week high of $16.74 and way higher than its 52-week low of $8.30.
Volume
Today’s last reported volume for FVCBankcorp is 53159 which is 42.54% above its average volume of 37293.
